Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The results of the SOLSTICE trial are promising and show that maribavir may help with post-transplant CMV viremia, including cases of drug-resistance for which there is an unmet need.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: SHP620
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021